What does Voyager Therapeutics, Inc. do?
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for…
What is Voyager Therapeutics, Inc.'s P/E and P/B ratio?
Voyager Therapeutics, Inc. has a P/E ratio of -1.0 and a P/B ratio of 0.74.
What is Voyager Therapeutics, Inc.'s debt-to-equity ratio?
Voyager Therapeutics, Inc. has a debt-to-equity ratio of 0.21.
How much does Voyager Therapeutics, Inc. owe compared with what it owns?
Voyager Therapeutics, Inc. owes $0.22 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Voyager Therapeutics, Inc.'s Positivity rank?
Voyager Therapeutics, Inc. is ranked #1,778 of 6,774 companies globally and #443 of 4,000 in United States on PositoAI, with a Positivity Score of 22,313.
Does Voyager Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Voyager Therapeutics, Inc..
Where can I read the latest news about Voyager Therapeutics, Inc.?
Recent headlines about Voyager Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Voyager Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Voyager Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.